BPS Assessment Ltd​

All over the world, avoidable medication errors are having real-life implications to patient safety. In the UK alone, for example, the cost of avoidable medication errors is around £98.5 million every year. BPS Assessment is continuing to change this through a suite of online learning resources that help clinical professionals prescribe safely and effectively. There have been some significant wins this year such as the collaboration with The University of Ryukyus in Japan and the co-development of new functionality with the University of Manchester.  

Our work with Clinical Pharmacologists in Japan has strengthened the Society’s ties with colleagues, sharing our expertise and building new opportunities to improve prescribing education on a global basis. Our thanks to Professor Simon Maxwell, Dr Lynne Bollington who have worked tirelessly to deliver this complex project in partnership with our Japanese colleagues, Professor Shinchiro Ueda, Professor Takako Okumura and colleagues. These developments offer the potential for growth long term. As a critical aspect of the Society’s income diversification strategy, it was pleasing to see BPS Assessment Ltd grow in strength and impact, achieving sales of £471,946 which equated to 111% of the target set by the budget.  Renewals have remained strong with 97% of renewals achieved.  The year ended with 41 continuing customers in total, 23 of which are on multi-year agreements.  

Developing new opportunities to support customers with their prescribing assessment needs is the foundation to future growth. The new Electronic Prescribing Simulator (EPS Simulator) went live in December.  The EPS Simulator offers schools the ability to create realistic prescribing scenarios on a system which accurately reflects a real hospital or GP ePrescribing system.  Demonstration content is currently being developed by our academic partners and once this is in place the system can be showcased to current and new customers, representing a potential new revenue stream. There is confirmed interest in the concept from several institutions. It is intended that the finalised product will be available for sale by the second quarter of 2025.   

---

Next: Financial statements
Previous: Our publishing portfolio​
Go back to Annual Review 2024